Coexistence of a Novel NBAS-ALK, EML4-ALK Double-Fusion in a Lung Adenocarcinoma Patient With LM and Response to Ensartinib

被引：0
|
作者：
Xu, X. [1 ,2 ,3 ]
Li, N. [1 ]
Fan, Y. [1 ,2 ]
机构：
[1] Univ Chinese Acad Sci, Canc Hosp, Zhejiang Canc Hosp, Hangzhou, Peoples R China
[2] Chinese Acad Sci, Hangzhou, Peoples R China
[3] Zhejiang Chinese Med Univ, Hangzhou, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2022年 / 17卷 / 09期
关键词：
ALK; non-small cell lung cancer (NSCLC); leptomeningeal metastases (LM);
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP08.02-09
引用
收藏
页码：S445 / S445
页数：1
相关论文
共 50 条
  • [1] Coexistence of a Novel PRKCB-ALK, EML4-ALK Double-Fusion in a Lung Adenocarcinoma Patient and Response to Crizotinib
    Luo, Jing
    Gu, Dejian
    Lu, Huasong
    Liu, Si
    Kong, Jinliang
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (12) : E266 - E268
  • [2] Coexistence of a novel NBEA-ALK, EML4-ALK double-fusion in a lung adenocarcinoma patient and response to alectinib: A case report
    Liang, Qi
    Xu, Huanhuan
    Liu, Yiqian
    Zhang, Weiming
    Sun, Chongqi
    Hu, Meng
    Zhu, Yizhi
    Tan, Shanyue
    Xu, Xian
    Wang, Sumeng
    Liu, Lingxiang
    LUNG CANCER, 2021, 162 : 86 - 89
  • [3] Coexistence of a secondary STRN-ALK, EML4-ALK double-fusion variant in a lung adenocarcinoma patient with EGFR mutation: a case report
    Zeng, Qian
    Gao, Han
    Zhang, Longdan
    Qin, Shouming
    Gu, Yongyao
    Chen, Quanfang
    ANTI-CANCER DRUGS, 2021, 32 (08) : 890 - 893
  • [4] Coexistence of a novel SV2B-ALK, EML4-ALK double-fusion in a lung poorly differentiated adenocarcinoma patient and response to alectinib: a case report and literature review
    Chen, Huang
    Zhang, Menglan
    Bai, Liyan
    Niu, Yun
    Wang, Xiaowei
    Jiang, Ruiying
    Wang, Ye
    Feng, Qianqian
    Wang, Bei
    Dai, Tingli
    Yuan, Mingming
    Chen, Rongrong
    Qi, Yujuan
    Zhong, Dingrong
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [5] Coexistence of a novel SETD2-ALK, EML4-ALK double-fusion in an advanced lung adenocarcinoma patient after alectinib resistant and response to immunotherapy combined with chemotherapy: a case report
    Lin Zhu
    Jing Qin
    Discover Oncology, 14
  • [6] Coexistence of a novel SETD2-ALK, EML4-ALK double-fusion in an advanced lung adenocarcinoma patient after alectinib resistant and response to immunotherapy combined with chemotherapy: a case report
    Zhu, Lin
    Qin, Jing
    DISCOVER ONCOLOGY, 2023, 14 (01)
  • [7] Concomitant novel ALK-SSH2, EML4-ALK and ARID2-ALK, EML4-ALK double-fusion variants and confer sensitivity to crizotinib in two lung adenocarcinoma patients, respectively
    Hong Tao
    Zhe Liu
    Jing Mu
    Fei Gai
    Zhan Huang
    Liang Shi
    Diagnostic Pathology, 17
  • [8] Concomitant novel ALK-SSH2, EML4-ALK and ARID2-ALK, EML4-ALK double-fusion variants and confer sensitivity to crizotinib in two lung adenocarcinoma patients, respectively
    Tao, Hong
    Liu, Zhe
    Mu, Jing
    Gai, Fei
    Huang, Zhan
    Shi, Liang
    DIAGNOSTIC PATHOLOGY, 2022, 17 (01)
  • [9] Novel NLRC4-ALK and EML4-ALK double fusion mutations in a lung adenocarcinoma patient: A case report
    Wu, Xueqian
    Wang, Weiya
    Zou, Bingwen
    Li, Yanying
    Yang, Xiaojuan
    Liu, Ning
    Ma, Qizhi
    Zhang, Xiaoxuan
    Wang, Yongsheng
    Li, Dan
    THORACIC CANCER, 2020, 11 (06) : 1695 - 1698
  • [10] Identification of a Novel EML4-ALK Fusion Transcript in Lung Adenocarcinoma
    To, K.
    Tong, J. H. M.
    Law, P. P. Y.
    Chau, S. L.
    Lung, R. W. M.
    Yeung, S. F.
    Kang, W.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (09) : S218 - S219
12345